The Latest Cardiac and Vascular News
CARLSBAD, Calif., May 11, 2023 (GLOBE NEWSWIRE) — Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today reported results for the first quarter of 2023. Recent Highlights: Reported revenue of $4.2 million for the first quarter of 2023, a […]
CARLSBAD, Calif., April 20, 2023 (GLOBE NEWSWIRE) — Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced preliminary unaudited results for the first quarter 2023 in addition to the release of the RECOVER AF study data (published online […]
CARLSBAD, Calif., April 20, 2023 (GLOBE NEWSWIRE) — Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced results from the RECOVER AF study. The study, published online in EP Europace, found that patients who received AcQMap-guided ablations for retreatment achieved better outcomes […]
Collaboration Aims to Explore Benefits of Remote Monitoring of Patients Pre- and Post-Ablation MOUNTAIN VIEW, Calif., July 27, 2021 /PRNewswire/ — AliveCor, Inc. (“AliveCor”), a leading innovator in FDA-cleared personal electrocardiogram (ECG) technology and services, and Acutus Medical (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced they will collaborate to […]
CARLSBAD, Calif., July 14, 2021 (GLOBE NEWSWIRE) — Acutus Medical, Inc. (Nasdaq: AFIB) (“Acutus”) today announced the pricing of its underwritten public offering of 5,500,000 shares of its common stock at a price to the public of $14.00 per share. All of the shares of common stock are being offered by Acutus. The gross proceeds […]
CARLSBAD, Calif., April 05, 2021 (GLOBE NEWSWIRE) — Acutus Medical (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced initial US enrollments in the company’s AcQForce™ Flutter Investigational Device Exemption (IDE) clinical trial. This trial is expected to enroll up to 150 subjects in leading […]
CARLSBAD, Calif., Jan. 13, 2021 (GLOBE NEWSWIRE) — Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today reported preliminary unaudited revenue results for the quarter and full year ended December 31, 2020. Preliminary Fourth Quarter and Full Year Results: Preliminary unaudited revenue […]
Design Features Improve Handling and Deliverability to Enhance Efficiency CARLSBAD, Calif., Sept. 17, 2020 (GLOBE NEWSWIRE) — Acutus Medical (Nasdaq: AFIB) today announces FDA 510(k) clearance of the second-generation AcQMap® 3D imaging and mapping catheter which builds on its predecessor, improving handling and deliverability. This flagship 3D mapping and navigation catheter combines 48 ultrasound transducers responsible for […]
CARLSBAD, Calif., Sept. 17, 2020 (GLOBE NEWSWIRE) — Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), today reported financial results for its second quarter ended June 30, 2020. Recent Highlights: Reported revenue of $1.1 million in the second quarter of 2020, a 54% increase over the same quarter last year and within the preliminary range disclosed in […]
CARLSBAD, Calif., Sept. 03, 2020 (GLOBE NEWSWIRE) — Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), today announced it will release its financial results for the second quarter of 2020 after market close on Thursday, September 17, 2020. In conjunction with the release, Acutus will host a conference call and webcast at 1:30 p.m. Pacific Time (4:30 […]
